Prognostic significance of cytokine levels in newly-diagnosed AML and high-risk myelodysplasia.

被引：0
|
作者：
Albitar, M [1 ]
Estey, E [1 ]
Doherty, D [1 ]
Shen, Y [1 ]
Cortes, J [1 ]
O'Brien, S [1 ]
Giles, F [1 ]
Kantarjian, H [1 ]
Kurzrock, R [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1382
引用
收藏
页码：327A / 327A
页数：1
相关论文
共 50 条
  • [41] A "first in man" study of the safety and PK/PD of an oral FLT3 inhibitor (MLN518) in patients with AML or high risk myelodysplasia.
    Heinrich, MC
    Druker, BJ
    Curtin, PT
    Paquette, R
    Sawyers, CL
    De Angelo, DJ
    Gilliland, GD
    Stone, RM
    Caliguiri, MA
    Byrd, JC
    Heaney, ML
    Nimer, SD
    Romanko, KP
    Lambing, JL
    Lokker, NA
    Giese, NA
    Gretler, DD
    BLOOD, 2002, 100 (11) : 336A - 337A
  • [42] Prognostic significance of early changes in serum biomarker levels in patients with newly diagnosed metastatic prostate cancer
    Narita, Shintaro
    Nomura, Kyoko
    Hatakeyama, Shingo
    Takahashi, Masahiro
    Sakurai, Toshihiko
    Kawamura, Sadafumi
    Hoshi, Senji
    Ishida, Masanori
    Kawaguchi, Toshiaki
    Ishidoya, Shigeto
    Shimoda, Jiro
    Sato, Hiromi
    Mitsuzuka, Koji
    Tochigi, Tatsuo
    Tsuchiya, Norihiko
    Ohyama, Chikara
    Arai, Yoichi
    Nagashima, Kengo
    Habuchi, Tomonori
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [43] PROGNOSTIC SIGNIFICANCE OF EARLY CHANGES IN SERUM BIOMARKER LEVELS IN PATIENTS WITH NEWLY DIAGNOSED METASTATIC PROSTATE CANCER
    Sato, Hiromi
    Narita, Shintaro
    Nomura, Kyoko
    Hatakeyama, Shingo
    Takahashi, Masahiro
    Sakurai, Toshihiko
    Kawamura, Sadafumi
    Hoshi, Senji
    Ishida, Masanori
    Kawaguchi, Toshiaki
    Ishidoya, Shigeto
    Shimoda, Jiro
    Mitsuzuka, Koji
    Tochigi, Tatsuo
    Tsuchiya, Norihiko
    Ohyama, Chikara
    Arai, Yoichi
    Habuchi, Tomonori
    JOURNAL OF UROLOGY, 2019, 201 (04): : E406 - E407
  • [44] Prognostic significance of early changes in serum biomarker levels in patients with newly diagnosed metastatic prostate cancer
    Shintaro Narita
    Kyoko Nomura
    Shingo Hatakeyama
    Masahiro Takahashi
    Toshihiko Sakurai
    Sadafumi Kawamura
    Senji Hoshi
    Masanori Ishida
    Toshiaki Kawaguchi
    Shigeto Ishidoya
    Jiro Shimoda
    Hiromi Sato
    Koji Mitsuzuka
    Tatsuo Tochigi
    Norihiko Tsuchiya
    Chikara Ohyama
    Yoichi Arai
    Kengo Nagashima
    Tomonori Habuchi
    Scientific Reports, 9
  • [45] Prognostic significance of myelodysplasia-related changes according to the WHO classification among ELN-intermediate-risk AML patients
    Devillier, Raynier
    Gelsi-Boyer, Veronique
    Murati, Anne
    Prebet, Thomas
    Rey, Jerome
    Etienne, Anne
    D'Incan, Evelyne
    Charbonnier, Aude
    Blaise, Didier
    Mozziconacci, Marie-Joelle
    Vey, Norbert
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (01) : E22 - E24
  • [46] Subnormal Vitamin D Levels Are Associated with Adverse Outcome In Newly-Diagnosed Similarly-Treated Adult Acute Myeloid Leukemia (AML) Patients
    Lee, Hun Ju
    Muindi, Josephia
    Wei, Tan
    Wilding, Gregory
    Ford, Laurie A.
    Sait, Sheila
    Block, Annmarie
    Barcos, Maurice
    Vigil, Carlos E.
    Griffiths, Elizabeth A.
    Thompson, James E.
    Wang, Eunice S.
    Johnson, Candace S.
    Trump, Donald
    Wetzler, Meir
    BLOOD, 2010, 116 (21) : 457 - 458
  • [47] Prognostic significance of coronary calcific deposits in asymptomatic high-risk subjects
    Detrano, RC
    Wong, ND
    Doherty, TM
    Shavelle, R
    AMERICAN JOURNAL OF MEDICINE, 1997, 102 (04): : 344 - 349
  • [48] Prognostic significance of neurological signs in high-risk infants - a systematic review
    Hamer, Elisa G.
    Hadders-Algra, Mijna
    DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2016, 58 : 53 - 60
  • [49] Outcome of Patients with Newly-Diagnosed Therapy-Related AML (t-AML) and AML with Myelodysplasia-Related Changes (AML-MRC) Treated with Liposomal Daunorubicin and Cytarabine (CPX-351) at an Academic Community-Based Health System
    Khoury, John
    Anusim, Nwabundo
    Macari, David
    Duenn, Angela
    Jaiyesimi, Ishmael
    BLOOD, 2019, 134
  • [50] Transplant outcomes after CPX-351 vs 7+3 in older adults with newly diagnosed high-risk and/or secondary AML
    Uy, Geoffrey L.
    Newell, Laura F.
    Lin, Tara L.
    Goldberg, Stuart L.
    Wieduwilt, Matthew J.
    Ryan, Robert J.
    Faderl, Stefan
    Lancet, Jeffrey E.
    BLOOD ADVANCES, 2022, 6 (17) : 4989 - 4993
12345